Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status Prescription; Discontinued
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 68071-4215; 23155-019; 70518-1829; 50090-0086; 49964-0018; 43353-495; 63629-5688; 70518-0185; 51927-0054; 51927-0081; 0591-0796; 0013-0101; 59762-0104; 38779-0176; 0013-0102; 50268-730; 59116-0632; 62705-0222; 62991-2704; 57294-021; 59116-0631; 71610-577; 59762-5000; 59116-0633; 59116-0630; 62135-960; 51552-1044; 50090-2013; 49452-7523; 68022-7065; 70518-2342
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Leukopenias NECCytochrome P450 1A2P05177Not Available11600468; 11856081; 11600469
VasculitisMyeloperoxidaseP05164T234717913504; 7913503; 8102951; 7914458; 8624621; 7869327; 7835022; 8095074; 8624617
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Microcephaly15.11.02.002; 03.11.02.0020.001382%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mouth ulceration07.05.06.0040.004835%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myelitis transverse10.04.10.006; 17.06.02.002--Not Available
Myelodysplastic syndrome16.01.04.001; 01.10.04.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocarditis02.04.03.0010.003454%
Nausea07.01.07.0010.074602%
Neck pain15.03.04.009--
Neoplasm malignant16.16.01.001--Not Available
Nephritis20.05.02.001--Not Available
Nephrolithiasis20.04.01.0020.004145%
Nephrotic syndrome20.05.01.0020.003454%
Nervous system disorder17.02.10.001--Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.0040.008289%Not Available
Normochromic normocytic anaemia01.03.02.0050.002072%Not Available
Oculomucocutaneous syndrome07.05.01.010; 06.04.05.014; 23.03.01.0220.002072%Not Available
Oedema14.05.06.010; 08.01.07.0060.003454%Not Available
Oligospermia21.03.03.005--
Oliguria20.01.03.004--Not Available
Oral mucosal blistering07.05.05.0170.001382%Not Available
Osteoarthritis15.01.04.0010.002072%Not Available
Osteomyelitis15.02.05.001; 11.01.01.0010.001382%
Pain08.01.08.004--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 15 Pages